PMID-10469335 – Thymosin beta4 accelerates wound healing
Malinda KM et al. "Thymosin beta4 accelerates wound healing," Journal of Investigative Dermatology, 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
Quick Reference
| Property | Value |
|---|---|
| PMID | 10469335 |
| DOI | 10.1046/j.1523-1747.1999.00708.x |
| Year | 1999 |
| Journal | Journal of Investigative Dermatology |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Rat full-thickness wound model |
| Peptide(s) Studied | TB-500 |
Key Findings
- Topical Tβ4 increased re-epithelialization by 42% over saline controls at day 4 and up to 61% at day 7
- Enhanced wound contraction, collagen deposition, and angiogenesis in treated wounds
- Stimulated keratinocyte migration in vitro at nanomolar concentrations
- Effective via both topical and systemic administration routes
Study Design
Controlled animal study using full-thickness dermal wounds in rats. Tβ4 applied topically or administered systemically. Outcomes: wound closure rate, histological analysis (re-epithelialization, collagen, blood vessel density), in vitro migration assays.
Limitations
- Animal model (rat); human skin healing dynamics differ
- Relatively small group sizes typical of late-1990s dermal wound studies
- Single-species validation
Clinical Relevance
Foundational study establishing Tβ4 as a wound healing agent. Published in the Journal of Investigative Dermatology (high-impact dermatology journal). The 42-61% improvement in re-epithelialization set the stage for all subsequent wound healing research with this peptide. Directly relevant to the Recovery Stack Protocol.
Related
#research #animal-in-vivo #evidence-level-V